VivoSim Labs, Inc. (VIVS) Stock Score, Valuation & Financial Research
VivoSim Labs, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for VIVS
VivoSim Labs, Inc. currently has a Wall Street Score of 19/100. The stored market price is $0.28. Its financial score is 4/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What VivoSim Labs, Inc. does
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, funct
VIVS financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $0.28
- Market capitalization:
- $729K
- Revenue:
- $131K
- Net income:
- $-13.8M
- Free cash flow:
- $-10.8M
- Cash:
- $5.0M
- Total debt:
- $447K
- EPS:
- -5.35
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-10.8M, showing cash burn in the current stored period.
- The balance sheet shows $5.0M of cash versus $447K of total debt, leaving more cash than debt.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VIVS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.